SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act 1934

Date of Report (Date of earliest event reported): March 21, 2013

 

 

Titan Pharmaceuticals, Inc.

(Exact name of registrant as specified in charter)

 

 

 

Delaware   0-27436   94-3171940

(State or Other Jurisdiction of

Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

400 Oyster Point Blvd., Suite 505, South San Francisco, CA   94080
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: 650-244-4990

(Former Name or Former Address, is Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Item 8.01. Other Events.

On March 21, 2013, Titan Pharmaceuticals, Inc. announced that the majority of the members of the Psychopharmacologic Drugs Advisory Committee of the U.S. Food and Drug Administration (the “FDA”) voted in favor of approval of Probuphine for the maintenance treatment of adult patients with opioid dependence. The FDA is not bound by the recommendation of its advisory committee, but will consider the committee’s guidance as it evaluates the Probuphine New Drug Application.

The press release dated March 21, 2013 is attached to this Current Report on Form 8-K as Exhibit 99.1 and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

 

99.1    Press Release dated March 21, 2013

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

TITAN PHARMACEUTICALS, INC.
By:  

/s/ Sunil Bhonsle

Name:   Sunil Bhonsle
Title:   President

Dated: March 22, 2013

Exhibit Index

 

Exhibit No.

   

Description

99.1    Press Release dated March 21, 2013